Atara Biotherapeutics Inc. (NASDAQ:ATRA) CFO John Mcgrath sold 5,000 shares of the firm’s stock in a transaction on Wednesday, October 12th. The stock was sold at an average price of $17.47, for a total transaction of $87,350.00. Following the completion of the sale, the chief financial officer now owns 96,823 shares of the company’s stock, valued at $1,691,497.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Atara Biotherapeutics Inc. (NASDAQ:ATRA) opened at 16.05 on Monday. The company’s market capitalization is $462.42 million. The company’s 50 day moving average is $19.63 and its 200-day moving average is $20.24. Atara Biotherapeutics Inc. has a 52-week low of $13.31 and a 52-week high of $40.80.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.05. Equities analysts anticipate that Atara Biotherapeutics Inc. will post ($2.85) EPS for the current fiscal year.
ATRA has been the subject of a number of research reports. Jefferies Group restated a “buy” rating and issued a $25.00 price target on shares of Atara Biotherapeutics in a report on Sunday, July 10th. JMP Securities restated a “buy” rating on shares of Atara Biotherapeutics in a report on Saturday, July 9th. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 10th. Citigroup Inc. raised their price objective on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a research note on Friday, August 19th. Finally, Goldman Sachs Group Inc. lowered shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $23.00 to $16.00 in a research note on Thursday, September 15th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $26.14.
A number of large investors have recently bought and sold shares of the stock. ProShare Advisors LLC raised its stake in Atara Biotherapeutics by 4.2% in the second quarter. ProShare Advisors LLC now owns 24,236 shares of the company’s stock worth $546,000 after buying an additional 980 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Atara Biotherapeutics by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 62,600 shares of the company’s stock worth $1,191,000 after buying an additional 1,900 shares during the last quarter. BlackRock Advisors LLC increased its position in shares of Atara Biotherapeutics by 30.2% in the second quarter. BlackRock Advisors LLC now owns 10,186 shares of the company’s stock worth $229,000 after buying an additional 2,361 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Atara Biotherapeutics by 23.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 16,200 shares of the company’s stock worth $365,000 after buying an additional 3,100 shares during the last quarter. Finally, American International Group Inc. increased its position in shares of Atara Biotherapeutics by 30.3% in the second quarter. American International Group Inc. now owns 13,371 shares of the company’s stock worth $301,000 after buying an additional 3,111 shares during the last quarter. Institutional investors own 75.58% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.